#astrazeneca

#astrazeneca

AstraZeneca's annual meeting is overshadowed by investigations and pay protests despite strong financial performance.

AstraZeneca cancelled a £450 million investment in the UK due to financial disagreements with the government.

AstraZeneca invests $2.5 billion in Beijing to bolster research, moving past recent controversies while collaborating with local biotech firms.

AstraZeneca's profits surged despite pulling back on investments due to unmet government support.

AstraZeneca aims for $80 billion in revenue by 2030, potentially exceeding $100 billion if growth continues.

AstraZeneca canceled a £450 million investment due to the UK government missing a key funding deadline, stalling the project's progress.

AstraZeneca cancels £450 million investment due to Labour's insufficient support compared to Conservatives.

Labour's reversal of the previous Chancellor's support affects AstraZeneca's expansion plans.

Government changes in investment terms led to AstraZeneca's decision against investment.

The Treasury is in talks with AstraZeneca regarding a £450 million vaccine facility, but funding support is significantly reduced, raising concerns about investment viability.

AstraZeneca's £450m investment in Liverpool signifies a renewed confidence in the UK's life sciences sector.

AstraZeneca cancels a £450 million investment in UK due to insufficient government support, indicating challenges in the life sciences sector.

AstraZeneca is cooperating with Chinese authorities amidst investigations into alleged illegal importation of cancer drugs.

AstraZeneca canceled its 450m vaccine factory expansion, revealing issues with government negotiations and corporate investment in the UK.

AstraZeneca threatened job cuts if UK enforces profit-sharing laws related to genetic codes in drug development.

AstraZeneca is cooperating with Chinese investigations into potential illegal activities, emphasizing its commitment to the Chinese market and innovative medicines.

AstraZeneca is withdrawing its Covid-19 vaccine due to newer, more targeted vaccines available for Covid-19 variants.

AstraZeneca has withdrawn its COVID-19 vaccine Vaxzevria globally due to declining demand and the availability of other updated vaccines.